Autologous Bone Marrow Transplantation in Acute Leukemia and Non-Hodgkin’s Lymphoma: A Phase I Study of 4-Hydroperoxycyclophosphamide (4HC) Incubation of Marrow prior to Cryopreservation
The presence of occult tumor cells in remission marrow is the initial obstacle to the use of autologous bone marrow transplantation in acute leukemia. In vitro treatment of tumor-marrow mixture, with heterologous antiserum and complement, has been shown to be capable of eliminating all clonogenic tumor in a number of animal models, and this approach forms the basis for a number of ongoing clinical trials . An alternative procedure, utilizing in vitro drug treatment of marrow, was first investigated at The Johns Hopkins Oncology Center using 4-hydroperoxycyclophosphamide (4HC). In aqueous solution, this congener of cyclophosphamide (CY) has the same alkylating and cytotoxic effects and the same immunoreactive products as the microsomally activated parent compound.
KeywordsAcute Leukemia Ongoing Clinical Trial Autologous Bone Marrow Transplantation Hematologic Recovery Reserve Fraction
- 1.Kaizer H, Santos G (1982) Autologous bone marrow transplantation in the treatment of cancer: Current status. In: Ariel I (ed) Progress in clinical cancer, Vol. 8. Grune and Stratton, New York pp 31–44Google Scholar
- 3.Kaizer H, Cote JP, Sharkis S, Stuart RK, Santos GW (1982) Autologous bone marrow transplantation in acute leukemia: The use of in vitro incubation of tumor-marrow mixtures with 4-hydroperoxycyclophosphamide (4HC) in a Wistar-Furth rat model of acute myelogenous leukemia (WF-AML). Proc Am Assoc Cancer Res 23:194Google Scholar